Study on Standard Evaluation System and Optimal Treatment Path of Senile Valvular Heart Disease


The key technology research and standard evaluation system of elderly heart valve disease evaluation is to further establish a domestic multi center and large sample full information big data platform of elderly heart valve disease based on the previous Chinese elderly valve disease cohort and clinical research platform and the national valve disease surgery data platform.

Full Title of Study: “China Degenerative Valve Disease II Cohort Study (China-DVD2 Study)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 2023

Detailed Description

Establish clinical and Imaging Database


  • Diagnostic Test: imaging
    • (1) Build the first full information big data cloud platform for diagnosis, treatment and clinical research of senile valvular disease in China (2) To establish a cohort of elderly patients with valvular disease in China and a complete database covering clinical information, functional, imaging evaluation, treatment and follow-up; (3) To analyze the clinical characteristics, functional status and imaging characteristics of senile valvular disease in China, and to understand the current situation of diagnosis and treatment; To establish a whole process standardized comprehensive evaluation system of clinical indicators of senile valvular disease combined with a variety of imaging for Chinese people.

Clinical Trial Outcome Measures

Primary Measures

  • all-cause mortality
    • Time Frame: Time Frame: 2years
    • all-cause mortality

Participating in This Clinical Trial

Inclusion Criteria

  • (1) Inclusion criteria:

Patients with heart valve disease who are ≥ 65 years old and diagnosed by echocardiography meet the requirements One of the following criteria: Severe mitral stenosis: valve orifice area < 1.0cm2; Severe mitral regurgitation: constriction neck width ≥ 7mm, or regurgitation per beat (regurgitation volume)≥ 60ml, or reflux beam area / left atrial area > 50%; Or effective reflux port area (eroa) ≥ 0.4cm2; Severe aortic stenosis: mean cross valve pressure difference ≥ 40mmhg, or maximum jet velocity ≥ 4m / s, orValve orifice area < 1.0cm2, it should be differentiated from left ventricular outflow tract stenosis; Severe aortic regurgitation: constriction neck width > 6mm, or each pulsation regurgitation ≥ 60ml, or regurgitation Flow fraction ≥ 50%, or jet width ≥ 65% of left ventricular outflow tract, or effective reflux orifice area (eroa) ≥0.3cm2; Severe tricuspid stenosis: mean cross valve pressure difference ≥ 5mmhg; Severe tricuspid regurgitation: constriction neck width ≥ 7mm, or effective regurgitation orifice area (eroa)≥0.4cm2; Severe pulmonary stenosis: the forward blood flow velocity is ≥ 4m / s, which should be differentiated from right ventricular outflow tract stenosis; Severe pulmonary valve regurgitation: massive regurgitation, wide constriction neck Exclusion Criteria:

  • Patients unwilling to accept registration and follow-up; Patients with mental illness who cannot cooperate with information collection and follow-up

Gender Eligibility: All

Minimum Age: 65 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Yongjian Wu
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Yongjian Wu, Chief physician – China National Center for Cardiovascular Diseases
  • Overall Official(s)
    • yongjian wu, doctor, Study Chair, Fuwai Hospital, National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences
  • Overall Contact(s)
    • haiyan xu, doctor, +86 13681012249,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.